| AKESIS PHARMA (AKES) |
|
|
| OTCBB:AKES |
Last Trade: Tuesday, February 03, 2009 @ 6:05:00 AM |
| Last Price: 0.0045 |
Change: ($0.00 0.0%) |
| Open: |
0.0041 |
Prev. Close: |
0.0045 |
| Day's High: |
0.005 |
Low: |
0.0041 |
| 52-Week High: |
0.90 |
52-Week Low: |
0.38 |
| Bid: |
0.0041 / 5,000 |
Ask: |
0.005 / 5,000 |
| Volume: |
0 |
Outstanding: |
0 |
| Market cap: |
-
|
|
|
|
|
| Akesis Pharmaceuticals is an early stage biopharmaceutical company engaged in the discovery, development and commercialization of complementary and alternative therapies for the treatment of three principal forms of carbohydrate intolerance ? Type 2 diabetes, Syndrome X, and impaired glucose tolerance (?IGT?) ? and their associated complications. Co. has been granted patents and filed patent applications for a number of proprietary combination therapies, including combinations with existing diabetes medications, for use in the treatment of Type 2 diabetes. The initial product candidate Co. developed, HEALTHPROPAK, is a patented combination of micronutrients. |
AKESIS PHARMA Press ReleasesAkesis Pharmaceuticals Discontinues Sole Clinical Development Program and Announces Intent to File f - Wednesday, January 21, 2009
Get this stock quote and other market data from XML Stock Quotes.com
|
